Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01129674 · ClinicalTrials.gov registry record · Phase 2
A Long-Term, Open-Label, Study on Schizophrenia
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1,210
- Enrollment target
NCT01129674: Clinical Trial Phase 2 study, sponsored by Eli Lilly and Company.
NCT01129674 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 1,210 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (810% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01129674, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1,210 participants
- Enrollment target
Study Summary
The primary purpose of the study is to help answer the following research questions: How LY 2140023 can be tolerated by patients with Schizophrenia compared to standard of care treatment in 52 weeks time period. Whether LY 2140023 can help patients with Schizophrenia.
Interventions
- DRUG Risperidone
- DRUG Olanzapine
- DRUG Quetiapine
- DRUG Aripiprazole
- DRUG LY2140023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,210 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Why NCT01129674 stopped before completion
NCT01129674 is an interventional study that assigns participants to a tested intervention. Its 1,210 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (810% higher).
The record links to 0 conditions, and to 5 interventions - of which Risperidone is the first listed.
NCT01129674 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01129674 about?
NCT01129674 is a clinical study titled "A Long-Term, Open-Label, Study on Schizophrenia". The primary purpose of the study is to help answer the following research questions: How LY 2140023 can be tolerated by patients with Schizophrenia compared to standard of care treatment in 52 weeks time period. Whether LY 2140023 can help patients with Schizophrenia.
What is the current status of trial NCT01129674?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1,210 participants. The study started on 2010-06. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01129674?
The interventions under investigation include: Risperidone (DRUG), Olanzapine (DRUG), Quetiapine (DRUG), Aripiprazole (DRUG), LY2140023 (DRUG).
Who is sponsoring clinical trial NCT01129674?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01129674's enrollment target sits among peer trials
1,210 17th of 2000 higher than 1,984 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- NCT06535854 · 1,205 participants · NA
Prevail Global Study
- NCT07223593 · 1,205 participants · Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia